Interpreta Founder and CEO, Ahmed Ghouri, M.D., presented at the Centene Corporation 14th Annual Investor Day in New York.
Dr. Ghouri outlined how Interpreta is building one of the world’s leading unified medical informatics platforms by leveraging 12+ years expertise in delivering real-time, scalable clinical analytics to Fortune 500 customers and key healthcare verticals.
Below is a transcript from that presentation.
AHMED GHOURI, M.D.
FOUNDER AND CHIEF EXECUTIVE OFFICER
Thank you, My name is Ahmed Ghouri. I’m the CEO of Interpreta. I’m also a physician by training and a biomedical engineer. Thank you for the opportunity for me to speak with you today. I’m very grateful.
The power of Interpreta is that it empowers the next generation of population health management, which is characterized by timely risk identification, meaning within 24 hours or less of a change in a member’s status. It transforms our ability to prioritize interventions. It changes the rules of engagement, with all users being on a real-time basis with different important stakeholders.
What we do specifically to enable these things is an industry first: We are doing real-time clinical and genomic interpretation.
You’ve probably read about personalized medicine, where we can tailor treatments to the DNA of a person. 20% to 30% of people may not respond to a certain class of medications; this is very important and it can be predicted in-silico with DNA sequences, for example.
But the DNA is not the whole story, right? A patient may not have preventative services; they may have lab results that are out of control. So what we need to do is combine these capabilities into a single real-time system.
Interpreta is building the world’s leading unified medical informatics platform. We’re leveraging a dozen years of expertise in delivering real-time analytics to multiple Fortune 500 customers that include payers, EMRs, hospitals, PBM, national labs, and personal health records.
For the first time in medicine we have delivered an architecture that solves multiple complex issues continuously and in real-time. So it’s not just fast, but it runs continuously; around the clock it follows every member every day, just like a GPS system.
Within this platform the engine computes all HEDIS and physician pay-for-performance quality measures; it analyzes the risk of the patient, including risk adjustment; it identifies therapeutic interchange possibilities; it expresses proprietary clinical rules that might be expressed by a payer or a hospital. It enhances medication safety; it measures medication adherence; it looks at drug safety at the genomic level using FDA rules; and it looks for drug efficacy at the genomic level using FDA rules.
It achieves this within clinical workflows so problems can be fixed before they manifest. And it does this in a secure cloud-based architecture, so it can massively scale and be available to organizations that don’t have unlimited IT resources.
This prospective analytics is based on NCQA-certified capabilities and IHA-certified capabilities for HEDIS and pay-for-performance. It enables CMS Stars optimization and risk adjustment optimization, medication adherence optimization, and context-specific drug gene alerts in a single real-time engine. I stress again, this is a unique capability in healthcare.
The real-time prospective analytics for the first time generates a forward view of a patient, rather than a rearview. Contemporary analytics is a report on the past.
What we’re doing with real-time analytics is creating a roadmap for a member that allows issues to be fixable within clinical workflow that actually predicts and prevents gaps in care, doesn’t react to them. It infers risk before bad things happen to the patient, and it generates a patient to-do list that is updated every 24 hours so that it’s clear what the patient needs for the next six to 12 months, and that picture is updated every single day.
The daily analyzer as well as a patient-specific calendar, generates a clinical state of the union on every member every day. This dashboard could be for a single member or single doctor’s practice, or 10 million members, computed hours ago.
What that does is it eliminates the surprises that are characteristic of latent reporting. This changes that paradigm.
The ability to do interpretation at both the macro clinical level and the microscopic level, all the way down to the genome, to make sure the drugs are personalized to that member, changes patient outcomes, maximizes quality-based revenue, and it reduces medical cost due to superior care.